A Systematic Review and Meta‐Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma

Propranolol offers a statistically significant advantage in achieving complete remission of infantile hemangioma compared to other active agents, while maintaining comparable overall response rates and a similar overall safety profile. These findings support propranolol as a first-line therapy when complete lesion resolution is the primary goal. Atenolol represents an effective alternative, particularly for patients with specific tolerability concerns, underscoring the need for individualized treatment selection.